arthritis, psoriatic

Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2
Andrew J K Ostor, Ahmed M Soliman, Kim A Papp, Byron Padilla, Zailong Wang, Ann Eldred, Kurt de Vlam, Alan Kivitz

RMD Open Jun 2022, 8 (2) e002286; DOI: 10.1136/rmdopen-2022-002286
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
Charlotte Krieckaert, Borja Hernández-Breijo, Johanna Elin Gehin, Guillaume le Mélédo, Alejandro Balsa, Meghna Jani, Denis Mulleman, Victoria Navarro-Compan, Gertjan Wolbink, John Isaac, Astrid van Tubergen

RMD Open Jun 2022, 8 (2) e002216; DOI: 10.1136/rmdopen-2022-002216
Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries
Florian Lucasson, Uta Kiltz, Umut Kalyoncu, Ying Ying Leung, Penélope Palominos, Juan D Cañete, Rossana Scrivo, Andra Balanescu, Emanuelle Dernis, Sandra Meisalu, Adeline Ryussen-Witrand, Martin Soubrier, Sibel Zehra Aydin, Lihi Eder, Inna Gaydukova, Ennio Lubrano, Pascal Richette, Elaine Husni, Laura C Coates, Maarten de Wit, Josef S Smolen, Ana-Maria Orbai, Laure Gossec

RMD Open May 2022, 8 (1) e002031; DOI: 10.1136/rmdopen-2021-002031
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
Iain B McInnes, Andrew J K Ostor, Philip J Mease, William Tillett, Xenofon Baraliakos, Kurt de Vlam, Louis Bessette, Ralph Lippe, Anna Maniccia, Dai Feng, Tianming Gao, Patrick Zueger, Christopher Saffore, Koji Kato, In-Ho Song, Atul Deodhar

RMD Open Mar 2022, 8 (1) e002049; DOI: 10.1136/rmdopen-2021-002049
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes
Iain B McInnes, Laura M Sawyer, Kristen Markus, Corinne LeReun, Celia Sabry-Grant, Philip S Helliwell

RMD Open Mar 2022, 8 (1) e002074; DOI: 10.1136/rmdopen-2021-002074
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
Christopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, John Tesser, Elena Schiopu, Soumya D Chakravarty, Alexa P Kollmeier, Xie L Xu, May Shawi, Yusang Jiang, Shihong Sheng, Yanli Wang, Stephen Xu, Joseph F Merola, Iain B McInnes, Atul Deodhar

RMD Open Mar 2022, 8 (1) e002195; DOI: 10.1136/rmdopen-2022-002195
Waiting for JAK inhibitor safety data
Tue Wenzel Kragstrup, Bente Glintborg, Annemarie L Svensson, Christopher McMaster, Philip C Robinson, Bent Deleuran, David FL Liew

RMD Open Feb 2022, 8 (1) e002236; DOI: 10.1136/rmdopen-2022-002236

Log in using your username and password

Main menu

Log in using your username and password

You are here

arthritis, psoriatic